Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance

Abstract

Twenty-two consecutive liver allograft recipients, who tested positive for immunoglobulin G (IgG) lymphocytotoxicity were subjected to pretransplantation and posttransplantation immunologic monitoring of anti-donor IgG lymphocytotoxic antibody titers, total hemolytic complement activity (CH100), circulating immune complexes (CIC), and platelet counts in an effort to improve our understanding of the preformed antibody state in clinical hepatic transplantation. Ten contemporaneous liver transplant recipients whose crossmatch results were negative and who experienced severe hepatocellular damage early after transplantation were included as controls. Crossmatch test results were negative 1 day after transplantation and during the 1 month follow-up remained negative in 14 of 22 (64%) sensitized recipients, most of whom had relatively low (< or = 1:16) anti-donor IgG antibody titers before transplantation. After transplantation, this group and the control group experienced no thrombocytopenia, no increase of CIC, and a gradual increase in CH100 activity that reached normal levels within 1 week. A strong negative correlation between prothrombin time (PT) and CH100 activity in these groups of patients suggested that changes in CH100 activity (P < .0005) were tightly linked to liver synthetic function. In contrast, the crossmatch test results remained positive after transplantation in 8 of 22 (36%) sensitized recipients, all of whom had relatively high (> 1:32 to 1024) pretransplantation titers of anti-donor IgG antibodies. After transplantation these patients developed a syndrome that was characterized by decreased CH100 activity and increased CIC compared with pretransplantation levels and refractory thrombocytopenia that was associated with a 50% allograft failure rate because of biopsy-proven humoral and acute (cellular) rejection.(ABSTRACT TRUNCATED AT 250 WORDS)

FIG. 1

Relationship between total CH₁₀₀ and time after transplantation in patients whose crossmatch results remained positive after transplantation (group A; dotted circle), patients whose crossmatch results became negative after transplantation (group B; closed circles), and patients with negative crossmatch results (group C; open circles).

FIG. 2

Relationship between CH₁₀₀ and PT in liver transplant recipients with negative crossmatch results and severe hepatocellular damage (A), liver transplant recipients with positive IgG lymphocytotoxic crossmatch results pretransplantation that became negative posttransplantation (B), and liver transplant recipients with positive IgG lymphocytotoxic crossmatch results pretransplantation and posttransplantation (C).